tbuckley/cabot-search huggingface dataset:
Pulmonary candidiasis and respiratory impairments among saw-mill workers
Authors: Subhabrata Moitra, Arghya Bandyopadhyay
Journal: European Respiratory Journal (2013)

Background   Saw-mill workers are exposed to a huge amount of wood dust. Although there are seminal reports about respiratory hazards among woodworkers, there is no report about the incidence of  Candida albicans  infection among them.   Objective   The study was carried out to see whether  C. albicans  infection could have additional effect on the pulmonary disturbances.   Methods   Out of 54 male saw-mill workers, based on the appearance of fungus in sputum, they were categorized in two groups,  Infected  (n=19, mean age 42±10 years) and  Non-infected  (n=35, mean age 37±5 years). Evaluation of the study participants included ECRHS questionnaire for any respiratory symptoms, lung function test (LFT) and pyrosequencing of the fungal 18s rDNA. Data of respiratory symptoms and association between fungus infection and lung function were analysed using odds ratio with 95% confidence interval and multiple regression respectively adjusting for age, smoking status, second hand smoke and parental asthma.   Results    C. albicans  was confirmed using BLAST of the sequences. The infected workers had significantly (p 1 , FEV 1 /FVC and FEF 25-75%  were lower among the infected workers although significance was observed for FEF 25-75%  (p C. albicans  infection and reduction of FEF 25-75%  [β= -0.26 (-0.53- -0.002)].   Interpretation    C. albicans  colonization imposed a greater prevalence of respiratory symptoms among the saw-mill workers and a higher chance of small airway obstruction.
Impact of Crizotinib on Patient-Reported Symptoms and Global Quality of Life (Qol) Compared with Platinum Based Chemotherapy in Phase III Study of Treatment Naïve Advanced Alk-Positive Non-Small Cell Lung Cancer (Nsclc)
Authors: F. Blackhall, E. Felip, F. Cappuzzo, D.W. Kim, Y. Wu, B. Solomon, K. Nakagawa, T. Mekhail, J. Paolini, T. Usari, S. Iyer, A. Reisman, K. Wilner, J. Tursi, T. Mok
Journal: Annals of Oncology (2014)
Limitations of positron emission tomography in predicting histopathologic response or prognosis following neoadjuvant chemoradiation for esophageal cancer
Authors: D. Vallbohmer, A. H. Holscher, M. Schmidt, E. Bollschweiler, S. Baldus, S. Monig, R. Metzger, P. M. Schneider, M. Dietlein
Journal: Journal of Clinical Oncology (2008)

4529 Background: Neoadjuvant chemoradiation is frequently applied to improve the prognosis of patients with advanced esophageal cancer. However, only a major histopathological response will provide a survival benefit. Recent studies suggest that [18F]-fluorodeoxyglucose-positron emission tomography during neoadjuvant chemotherapy significantly correlates with histopathological response and survival in patients with resected esophageal adenocarcinoma. Aim of this study was to evaluate the predictive and prognostic potential of FDG-PET in the multimodality treatment of patients with esophageal cancer. Methods: Study patients were recruited from a prospective clinical observation trial on neoadjuvant chemoradiation for esophageal cancer between 1997 and 2006. 133 patients with advanced esophageal cancer (uT2–4, Nx, M0) were included. All patients received neoadjuvant chemoradiation (cisplatin, 5-FU, 36 Gy) and underwent transthoracic en bloc esophagectomy. Histomorphologic regression was defined as major histopathological response when resected specimens contained less than 10 % vital residual tumor cells (major response: 52 patients; minor response: 81 patients). FDG-PET was performed before and 3–4 weeks after the end of chemoradiation with assessment of the intratumoral FDG-uptake [pre-treatment standardized uptake value (SUV1); post-treatment SUV(SUV2); percentage change (SUVΔ%)]. These variables were correlated with histopathological response and survival. Results: Neoadjuvant chemoradiation led to a significant reduction of intratumoral FDG-uptake (p<0.0001). No significant correlations between SUV1 or SUV2 and histopathological response or prognosis were found. Also, the SUVΔ% did not show any impact: SUVΔ% major response: SUVΔ% minor response=69%/57%. A SUV threshold with predictive or prognostic value was not identified. Histomorphological tumor regression was confirmed as an important prognostic factor (p<0.05). Conclusions: Our study does not support recent reports that the metabolic response by FDG-PET is associated with histomorphological response or survival in patients with esophageal cancer following neoadjuvant therapy and esophagectomy. No significant financial relationships to disclose.
P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure
Authors: C. Bernsmeier, R. Tidswell, L Ghataore, V.C. Patel, A. Singanayagam, E. Triantafyllou, W. Khamri, M. Heneghan, C. Willars, W. Bernal, G. Auzinger, D.R. Taylor, R.P. Vincent, Y. Ma, M.R. Thursz, J.A. Wendon, C.G. Antoniades
Journal: Journal of Hepatology (2015)
Anemia and early mortality in solid tumor and lymphoma patients receiving chemotherapy
Authors: J. Crawford, D. C. Dale, E. Culakova, M. S. Poniewierski, D. A. Wolff, G. H. Lyman
Journal: Journal of Clinical Oncology (2008)

20577 Background: Anemia is a common complication of cancer chemotherapy associated with considerable morbidity and cost. Guidelines recommend consideration of erythroid stimulating agents (ESAs) for hemoglobin (Hb) ≤10 g/dL. The relationship between anemia and mortality in cancer patients with multiple comorbid conditions has not been closely studied. Methods: A prospective observational study of 4,458 adult cancer patients initiating a new chemotherapy regimen was conducted at randomly selected U.S. practice sites. Data on demographics, comorbidities, cancer type and stage as well as chemotherapy and its complications were recorded. Overall survival (OS) during or within 60 days of chemotherapy was estimated and hazard ratios (HR) for OS were based on a Cox regression model incorporating time-dependent covariates. Results: During a median period of observation of 75 (range 1–385) days, 137 (3.1%) patients died including 88 of presumed progressive disease. Patient age ranged from 18 to 97 with 41% ≥65 years, 46% ECOG PS ≥1 and 38% with stage 4 disease. Predictors of early all-cause mortality in univariate analysis included: history of anemia (P<0.0001), low pretreatment Hb (P<0.0001) and drop in Hb from baseline (P<.0001) as well as age, ECOG PS, several comorbidities, cancer type and stage. Shorter time to tumor progression was associated with low baseline Hb (P=0.0120) and low Hb nadir in cycle 1 (P=0.0038). In multivariate analysis, the time-dependent occurrence of Hb <10 g/dL during chemotherapy remains significantly associated with OS [HR=1.60; 95%CI: 1.03–2.44; P=0.0350] with adjustment for patient age, gender, race, ethnicity, ECOG PS, Charlson comorbidity index, cancer type, stage, chemotherapy dose intensity, baseline laboratory abnormalities, year of study stratified by practice site. While use of ESAs or blood transfusion were associated with a reduction in the risk of early mortality in multivariate analysis, they were employed at the discretion of the treating oncologist. Conclusions: While controversy continues around the ESAs, this study demonstrates that baseline and subsequent anemia are associated with early all-cause mortality in unselected cancer patients receiving chemotherapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Amgen Amgen
A gene signature completely identifies metastasized testis tumors
Authors: M. Port, Y. Wang, H. U. Schmelz, T. Pottek, C. Ruf, M. Abend
Journal: Journal of Clinical Oncology (2008)

22144 Background: Selection of gene targets to distinguish metastasized from non-metastasized seminoma. Methods: Total RNA was isolated from metastasized seminoma (n=10, T1–3N0M0 to T1N1–2M0), non-metastasized seminoma (n=21) and corresponding normal tissues. The RNA from 10 biopsies of each tissue type was pooled and separately hybridized on four whole genome microarrays (Human Genome Survey Microarray V2.0, Applied Biosystem) for screening purposes. 92 selected gene candidates were then quantitatively examined using RTQ-PCR. Results: Agreement in gene expression was 88% between the whole genome microarrays and RTQ-PCR. Metastasized seminoma showed 1,912 upregulated and 2,179 downregulated genes with ≥ 2-fold differences in gene expression as compared to non-metastasized seminoma. The number of upregulated genes coding for immunity and defense, cell signaling and developmental processes were significantly overrepresented. RTQ-PCR showed that mean gene expression values of the 92 genes in general were significantly reduced in metastasized compared to non-metastasized seminoma. The presence of metastases could be completely predicted (100% specificity) based on a 85-gene expression signature by using Logistic Regression. Accompanied sensitivity and accuracy of the 10-fold crossvalidation model were 77.8% and 84.2%, respectively. Conclusions: A logistic regression model using the 85 gene expression signature allowed complete identification of metastasized seminoma. No significant financial relationships to disclose.
Quantitative Analysis of Dose-Response Data Obtained With Carcinogenic Hydrocarbons
Authors: W. Ray Bryan, Michael B. Shimkin
Journal: JNCI Journal of the National Cancer Institute (1941)

Quantitative Analysis of Dose-Response Data Obtained With Carcinogenic Hydrocarbons Get access W. Ray Bryan, W. Ray Bryan research fellow National Cancer Institute, National Institute of Health, United States Public Health Service1 Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin Michael B. Shimkin assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service1 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 6, June 1941, Pages 807–833, https://doi.org/10.1093/jnci/1.6.807 Published: 01 June 1941
Zika virus is a global public health emergency, declares WHO
Authors: Anne Gulland
Journal: BMJ (2016)

The Zika virus, and its suspected link to an increase in the number of babies born with microcephaly and a spike in neurological conditions is a global public health emergency, the World Health Organization has declared.1 2 3 4 5 6

WHO’s public health emergency committee, which met on Monday 1 February, declared that the spread of the virus was an emergency of public health concern, triggering funding into research, vector control, and efforts to stop pregnant women becoming infected.

WHO’s director general, Margaret Chan, told a press conference that the virus was an “extraordinary event and a public health threat to other parts of the world.” She said that evidence for a link between the virus and the increase in cases of microcephaly in babies and a spike in cases of …
Atrial fibrillation, a treatable disease? (developments in cardiovascular medicine, vol 139): Edited by J H Kingma, N M van Hemel, and K I Lie. (Pp 297; 52.) Dordrecht: Kluwer, 1992. ISBN 0-7923-2008-5
Authors: C.-M. Pripp
Journal: Cardiovascular Research (1995)

Atrial fibrillation, a treatable disease? (developments in cardiovascular medicine, vol 139): Edited by J H Kingma, N M van Hemel, and K I Lie. (Pp 297; £52.) Dordrecht: Kluwer, 1992. ISBN 0-7923-2008-5 Atrial fibrillation, a treatable disease? (developments in cardiovascular medicine, vol 139). Edited by Kingma J H van Hemel N M Lie K I. (Pp 297; £52.) Dordrecht: Kluwer, 1992. ISBN 0-7923-2008-5. Carl-Magnus Pripp Carl-Magnus Pripp Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 29, Issue 3, March 1995, Page 440, https://doi.org/10.1016/S0008-6363(95)90025-X Published: 01 March 1995
Tumorigenicity Test of 1,3- and 1,8-Dinitropyrene in BALB/c Mice&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: T Otofuji, K Horikawa, T Maeda, N Sano, K Izumi, H Otsuka, H Tokiwa
Journal: JNCI Journal of the National Cancer Institute (1987)

1,3-Dinitropyrene (DNP) and 1,8-DNP (CAS: 42397-65-9) are very potent mutagens and induce a frameshift-type mutation in the Salmonella test system. Each compound was tested for tumorigenicity in BALB/c mice by sc inoculation of 0.05 mg of the compound once a week for 20 weeks. Tumors developed at the site of injection of 1,8-DNP in 6 of 15 mice up to 60 weeks after the first injection. The incidence of tumors was statistically significant at a P-value of less than .05 but not of less than .01. Therefore, the carcinogenicity of 1,8-DNP in BALB/c mice was concluded to be weaker than that of benzo[a]pyrene [(BP) CAS: 50-32-8], which induced a 100% tumor incidence when it was injected at the same dose as that of 1,8-DNP. No tumors occurred at the injection site in mice given 1,3-DNP. Most of the tumors induced by 1,8-DNP and BP showed histologic features characteristic of malignant fibrous histiocytoma.
Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant Therapy Without Causing Severe Hemorrhagic Events
Authors: Naoki Kurita, Masanori Seki, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Naoshi Obara, Kazumi Suzukawa, Yuichi Hasegawa, Shigeru Chiba
Journal: Blood (2013)
Abstract 15648: Expression of Cavoelin-3 Improves Mitochondrial Function Aad Reduces Oxidative Stress in Heart Failure
Authors: Sameh S Ali, N Chin Lai, J Cameron Finley, Hemal H Patel, David M Roth
Journal: Circulation (2012)

Mitochondrial dysfunction is a critical element of heart failure progression. Caveolins have been found in mitochondria, however the role of caveolins and their effects on mitochondrial function in...
Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms.
Authors: I. E. Krop, L. Flores, D. P. Tuck, P. D. Ryan, A. H. Partridge, D. Morganstern, J. Najita, K. lezon-Geyda, E. P. Winer, L. Harris
Journal: Journal of Clinical Oncology (2010)

549 Background: Alterations in the PI3-Kinase (PI3K) pathway, loss of HER2 amplification, and activation of growth factor receptors have all been implicated in resistance to H. This preoperative study evaluated two H-based regimens and explored resistance mechanisms. Methods: 80 planned patients (pts) with stage II/III HER2+ disease underwent biopsies at baseline and 7-14d after a single dose of H (8 mg/kg) before starting chemotherapy. 67 pts were randomized to 12 weeks of VH (V 25 mg/m2 qwk + H 2mg/kg qwk) or 12 weeks of TCH (docetaxel 75 mg/m2 q3wk + C AUC 6 q3wk + H 2 mg/kg qwk) and 13 were treated (8 VH, 5 TCH) based on physician choice prior to definitive surgery. Pathologic complete response in breast/nodes (pCR) was assessed. Correlative studies included expression profiling at baseline and post-H monotherapy, PIK3CA mutation screen, baseline and posttreatment HER2 and EGFR FISH. Amplification was defined as HER2/CEP17 or EGFR/CEP7 ≥ 2.0. Results: 7/41 pts treated with VH (17%, CI = 10%-41%) and 11/39 pts treated with TCH (28%, CI = 15%-45%) had a pCR. Clinical response rates were 80% and 95%, respectively. For correlative analyses, all patients were assessed together. Only 2 /38 pts (5%) with evaluable samples had loss of HER2 amplification in their residual invasive cancer at surgery. EGFR amplification was rare (2/59=3%) in baseline samples, but 11/48 (23%) evaluable patients had gain of EGFR amplification in their residual disease. AKT activation gene signature prior to treatment was not associated with clinical response; AKT activation signature after a single dose of H was associated with a trend toward poor clinical response (p = 0.076). 0 of 9 pts with pCR had a PIK3CA mutation while 8 of 33 pts without pCR had a PIK3CA mutation (p = 0.3). Conclusions: In contrast to previous studies, loss of HER2 amplification was not a common mechanism of resistance. A non-significant relationship between clinical response and failure to suppress an AKT activation signature after a dose of H is of interest and warrants further study. Gain of EGFR amplification was observed in a substantial percentage of pts after treatment. Additional correlative data will be presented. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech
Incidence, characterization and clinical implications of sleep disorders in patients with atrial flutter
Authors: Nuria Grau, Victor Bazan, Miquel Felez, Carles Sanjuas, Julio Marti-Almor, Joaquim Gea
Journal: European Respiratory Journal (2011)

Background:  Sleep apnea-hypopnea syndrome (SAHS) is prevalent in patients with atrial fibrillation (AFib). It is unclear whether atrial flutter (AF) is accompanied by a high incidence of SAHS and impaired pulmonary function.   Methods:  We included 48 patients with AF, 26 and 22 of whom did not have and had associated AFib (groups 1 and 2, respectively). Fourteen patients with lone atrial fibrillation (group 3) and a matched control population (group 4, n= 50) with similar demographics, including body mass index (BMI) and incidence of hypertension and structural heart disease (SHD) served as control groups. Pulmonary function was assessed by using FEV 1 , FVC and FEV 1 /FVC. Sleep disorders were analyzed by using the apnea-hypopnea (AHI) and CT90 indexes and Epworth sleepiness scale (ESS).   Results:  Group 1 and 2 had similar demographics (19 male, 67±9 years, BMI 32±6 kg/m 2 ; and 13 male, 65±10 years, 33±8 kg/m 2 , respectively) and were older than group 3 (56±10 years, p   Conclusions:  The incidence of SAHS in patients with isolated atrial flutter is high and its specific treatment results in a more favorable arrhythmia control outcome.
Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients.
Authors: T M Beck, N E Hart, D A Woodard, C E Smith
Journal: Journal of Clinical Oncology (1983)

Local or regional recurrence after primary surgical management for carcinoma of the breast was retrospectively evaluated by presenting stage and management in 121 patients. None had evidence of systemic disease. Management consisted of surgical removal only in 11 patients, removal followed by irradiation in 25, biopsy only followed by irradiation in 43, hormonal therapy after biopsy in 30, and chemotherapy after biopsy in 12. Mean and median follow-up for all patients was 46.9 and 31.5 months, respectively. Patients experiencing a recurrence within 24 months of primary surgical management experienced the worst overall and disease-free survival. The group of 42 patients with residual disease who received systemic therapy after biopsy had improved disease-free and overall survival at 5 years in comparison to the group of 43 patients who received local therapy after biopsy (p less than or equal to 0.05). Radiation therapy produced more frequent and durable control of local disease than did systemic therapy. Patients who had a complete response to applied therapy had significant improvement in overall survival.
P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial
Authors: T.W. Welzel, K.R. Reddy, S.L. Flamm, J. Denning, S. Arterburn, T. Brandt-Sarif, P.S. Pang, J.G. McHutchison, M. Charlton, G.T. Everson, S. Zeuzem, N. Afdhal
Journal: Journal of Hepatology (2015)
Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma.
Authors: M J Watts, A M Sullivan, E Jamieson, R Pearce, A Fielding, S Devereux, A H Goldstone, D C Linch
Journal: Journal of Clinical Oncology (1997)

PURPOSE To define parameters that predict for rapid engraftment after peripheral-blood stem-cell (PBSC) transplantation, progenitor thresholds, the proportion of patients who achieve these thresholds with a standardized mobilization regimen, and the factors that predict for mobilization efficiency. PATIENTS AND METHODS One hundred and one patients with pretreated lymphoma were mobilized with cyclophosphamide 1.5 g/m2 and granulocyte colony-stimulating factor (G-CSF), with the first apheresis performed when the recovery WBC count was &gt; or = 5.0 x 10(9)/L. The relationship between the number of progenitor cells collected and patient age, sex, diagnosis, prior radiotherapy, and time since last chemotherapy was determined by multivariate analysis. The relationship between these factors, progenitor numbers returned, post-PBSC G-CSF, and hematologic recovery was performed in 81 patients following chemotherapy with carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM protocol). RESULTS No BEAM recipients had delayed neutrophil recovery beyond 28 days. Delayed platelet recovery occurred in 7.4% and minimum and optimum thresholds of 1 x 10(6) and 3.5 x 10(6) CD34+ cells/kg and 1 x 10(5) and 3.5 x 10(5) granulocyte-macrophage colony-forming cells (GM-CFC)/kg were established. Hematologic recovery was adversely affected by prior treatment with mini-BEAM, and neutrophil recovery was accelerated by post-PBSC G-CSF. The minimum GM-CFC threshold was achieved with a single apheresis in 83% of patients and in 90% with two aphereses. The optimal threshold was achieved with two leukaphereses in 69% of patients. Prior radiotherapy adversely affected mobilization. CONCLUSION Hematopoietic recovery following PBSC is dependent on progenitor-cell number infused and affect of previous chemotherapy on progenitor quality. Progenitor-cell mobilization is adversely affected by prior radiotherapy. The minimum threshold of GM-CFC required is achieved in most patients with a single apheresis, but an optimal collection usually requires at least two harvests.